Investigating Incretin-based Therapies As a Novel Treatment for Depression in Type 2 Diabetes: Findings from the South London Diabetes (SOUL-D) Study

Overview

Journal Prim Care Diabetes

Publisher Elsevier

Specialties Endocrinology
Public Health

Date 2015 Jul 4

PMID 26137918

Citations 10

Authors

C D Moulton

J C Pickup

S A Amiel

K Winkley

K Ismail

Affiliations

Soon will be listed here.

Abstract

We aimed to investigate the association between incretin-based therapies and 1-year change in depressive symptoms in a cohort of 1735 patients with newly diagnosed type 2 diabetes. The incretin group experienced significant reduction in depressive symptoms compared to controls. This was independent of HbA1c and may be mediated by an anti-inflammatory mechanism.

Citing Articles

Anti-Neuroinflammatory Effects of a Macrocyclic Peptide-Peptoid Hybrid in Lipopolysaccharide-Stimulated BV2 Microglial Cells.

Sun L, Saliba S, Apweiler M, Akmermer K, Herlan C, Grathwol C Int J Mol Sci. 2024; 25(8).

PMID: 38674048 PMC: 11049839. DOI: 10.3390/ijms25084462.

Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit.

Tempia Valenta S, Stecchi M, Perazza F, Nuccitelli C, Villanova N, Pironi L Eat Weight Disord. 2023; 28(1):99.

PMID: 38015342 PMC: 10684642. DOI: 10.1007/s40519-023-01625-5.

Comparing sodium-glucose cotransporter 2 inhibitors and dipeptidyl peptidase-4 inhibitors on new-onset depression: a propensity score-matched study in Hong Kong.

Mui J, Li L, Chou O, Azfar N, Lee A, Hui J Acta Diabetol. 2023; 60(7):917-927.

PMID: 37000300 PMC: 10198893. DOI: 10.1007/s00592-023-02063-6.

The Impact of Various Methods of Obesity Treatment on the Quality of Life and Mental Health-A Narrative Review.

Hachula M, Kosowski M, Zielanska K, Basiak M, Okopien B Int J Environ Res Public Health. 2023; 20(3).

PMID: 36767489 PMC: 9915720. DOI: 10.3390/ijerph20032122.

The Impact of Type 2 Diabetes in Parkinson's Disease.

Athauda D, Evans J, Wernick A, Virdi G, Choi M, Lawton M Mov Disord. 2022; 37(8):1612-1623.

PMID: 35699244 PMC: 9543753. DOI: 10.1002/mds.29122.